ICM
IART icon

Invenomic Capital Management’s Integra LifeSciences IART Stock Holding History

Invenomic Capital Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Sell
579,036
-432,279
-43% -$6.05M 0.62% 54
2026
Q1 		$9.53M Sell
1,011,315
-44,626
-4% -$490K 0.44% 69
2025
Q4 		$13.1M Buy
1,055,941
+463,729
+78% +$6.17M 0.61% 57
2025
Q3 		$8.49M Buy
592,212
+39,998
+7% +$548K 0.41% 77
2025
Q2 		$6.78M Buy
+552,214
New +$8.02M 0.38% 80

Other funds holding IART

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Invenomic Capital Management's IART Position: Q2 2026 in Review

Invenomic Capital Management reduced its Integra LifeSciences (IART) stake by 43% in Q2 2026, selling an estimated $6.05M and leaving 579,036 shares worth $10.4M. The position accounts for 0.62% of the portfolio, ranked #54.

Invenomic Capital Management first reported a position in IART in Q2 2025 and has held it in 5 quarters since. The position peaked at $13.1M in Q4 2025. 212 funds tracked by Wall St. Rank hold IART as of Q2 2026.

  • Invenomic Capital Management held 579,036 shares of Integra LifeSciences worth $10.4M as of Q2 2026.
  • Invenomic Capital Management sold 432,279 Integra LifeSciences shares in Q2 2026, an estimated $6.05M.
  • Integra LifeSciences made up 0.62% of Invenomic Capital Management's portfolio in Q2 2026, its #54 holding.
  • Invenomic Capital Management first reported a position in Integra LifeSciences in Q2 2025 and has held it in 5 quarters since.
  • Invenomic Capital Management's Integra LifeSciences position peaked at $13.1M in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on Invenomic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.